| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 4, 2026 | $6.04 | +61.5% | $112.03B | +0.4% | $4.84 |
| Q1 FY26ended Mar 31, 2026 | Apr 22, 2026 | $6.90 | +0.7% | $110.59B | +1.9% | $6.78 |
| Q4 FY25ended Dec 31, 2025 | — | $0.01 | −99.8% | $113.22B | +12.3% | — |
| Q3 FY25ended Sep 30, 2025 | — | $2.59 | −60.2% | $113.16B | +12.2% | — |
| Q2 FY25ended Jun 30, 2025 | — | $3.74 | −17.6% | $111.62B | +12.9% | — |
| Q1 FY25ended Mar 31, 2025 | — | $6.85 | — | $108.54B | +8.8% | — |
| Q4 FY24ended Dec 31, 2024 | — | $5.92 | +1.2% | $100.81B | +6.8% | — |
| Q3 FY24ended Sep 30, 2024 | — | $6.51 | +4.3% | $100.82B | +9.2% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe UnitedHealth shares, not any token. As of Aug 4, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $4.54 | — | $98.86B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | −$1.53 | — | $99.80B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $5.85 | — | $94.43B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $6.24 | — | $92.36B | — | — |
